Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been
the mainstay of therapy for> 60 years, but both classes of agents have limitations. The “ideal” …

Aim Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention …

As an alternative to the inconvenient and labor intensive traditional anticoagulants, Factor
Xa inhibitors may offer new options for the prevention and treatment of acute coronary …

Stroke prevention in atrial fibrillation (AF) has been challenging over decades, mostly due to
a number of difficulties associated with oral vitamin K antagonists (VKAs), which have been …

Background: Anticoagulation is recommended as standard of care for venous
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level
monitoring are presently undergoing taut scrutiny for efficacies and potential side effects …

Atrial fibrillation is the most common cause of stroke. Treatment with anticoagulants in
patients with atrial fibrillation reduces embolic complications of the disease including stroke …

Apixaban is an oral, direct factor Xa inhibitor indicated for the prevention and treatment of
thromboembolic disease. This randomized, blinded, 4‐way crossover study investigated the …

Background: Direct fXa inhibitors have become an important therapeutic option due to their
advantages in efficacy and safety. However, bleeding remains the major adverse effect and …

Background Clinical situations occur where expedient assessment of the anticoagulant
activity of the direct factor Xa (FXa) inhibitors is required. Although quantitative anti‐FXa …